Page last updated: 2024-10-28

gyki 52466 and Neoplasms

gyki 52466 has been researched along with Neoplasms in 2 studies

GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"These findings suggest anticancer potential of glutamate antagonists."1.31Glutamate antagonists limit tumor growth. ( Ikonomidou, C; Rzeski, W; Turski, L, 2001)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rzeski, W1
Turski, L1
Ikonomidou, C1
Cavalheiro, EA1
Olney, JW1

Other Studies

2 other studies available for gyki 52466 and Neoplasms

ArticleYear
Glutamate antagonists limit tumor growth.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, May-22, Volume: 98, Issue:11

    Topics: Anti-Anxiety Agents; Antineoplastic Agents; Benzodiazepines; Cell Division; Cell Movement; Cisplatin

2001
Glutamate antagonists: deadly liaisons with cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, May-22, Volume: 98, Issue:11

    Topics: Animals; Anti-Anxiety Agents; Antineoplastic Agents; Benzodiazepines; Cell Movement; Dizocilpine Mal

2001